BioCryst Pharmaceuticals (BCRX) said Wednesday it received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act with respect to the company's proposed acquisition of Astria Therapeutics.
The termination satisfied one of the conditions for the deal's completion, expected in Q1, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments